Biogen - 31 Year Stock Price History | BIIB

Historical daily share price chart and data for Biogen since 1991 adjusted for splits. The latest closing stock price for Biogen as of December 02, 2022 is 298.90.
  • The all-time high Biogen stock closing price was 438.73 on March 20, 2015.
  • The Biogen 52-week high stock price is 311.88, which is 4.3% above the current share price.
  • The Biogen 52-week low stock price is 187.16, which is 37.4% below the current share price.
  • The average Biogen stock price for the last 52 weeks is 225.53.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Biogen Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2022 224.7087 244.1400 306.7200 187.5400 298.9000 24.58%
2021 289.5569 242.9500 414.7100 223.9200 239.9200 -2.02%
2020 285.3138 294.2400 355.6300 236.2600 244.8600 -17.48%
2019 263.5519 304.6900 338.9600 216.7100 296.7300 -1.39%
2018 313.6443 334.1700 383.8300 257.5200 300.9200 -5.54%
2017 289.1924 268.8803 344.5800 246.5400 318.5700 21.88%
2016 258.2701 271.5625 304.2750 207.0224 261.3865 -7.43%
2015 324.9891 315.2437 438.7290 236.0019 282.3745 -9.75%
2014 293.0971 258.3909 332.4433 252.1115 312.8840 21.42%
2013 198.4327 138.2607 272.7239 131.6427 257.6922 91.00%
2012 125.8311 104.6173 143.8465 104.6173 134.9148 33.00%
2011 84.7777 61.9408 109.4288 59.9867 101.4373 64.13%
2010 51.9472 49.4420 62.8810 42.6027 61.8025 25.33%
2009 45.1133 44.6951 49.4973 38.8328 49.3130 12.32%
2008 51.0893 51.4975 65.7937 35.9662 43.9024 -16.32%
2007 52.1588 45.4693 76.0526 39.7546 52.4653 15.71%
2006 42.3905 43.0820 48.1700 37.5424 45.3403 8.64%
2005 39.8850 61.1020 62.4939 30.7400 41.7363 -32.02%
2004 52.7677 34.0490 62.6045 34.0490 61.3970 81.50%
2003 31.7365 31.6525 38.3167 25.8916 33.8278 10.64%
2002 43.7536 62.8165 65.4065 27.7904 30.5741 -51.88%
2001 52.5351 54.6130 68.7340 32.8968 63.5354 9.09%
2000 40.8053 28.6507 69.2072 17.6298 58.2416 92.94%
1999 12.9850 7.1819 30.1869 6.3185 30.1869 318.08%
1998 5.0456 5.2032 7.3923 2.6884 7.2203 36.71%
1997 4.3215 3.4565 7.0667 2.4964 5.2816 44.76%
1996 3.4365 2.9373 4.6271 2.2460 3.6485 21.80%
1995 1.0523 0.3641 3.5533 0.3457 2.9956 815.53%
1994 0.5396 0.8634 0.9985 0.3272 0.3272 -62.96%
1993 0.8822 1.3826 1.3826 0.5761 0.8833 -34.29%
1992 1.5007 1.9587 3.0725 0.9601 1.3442 -32.69%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $43.042B $10.982B
Biogen Inc. is one of the world's leading biotechnology companies which focuses on developing innovative therapies for treating serious neurological and neurodegenerative diseases, including its core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease (AD) and dementia, movement disorders including Parkinson's disease, neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS) and ophthalmology. Key multiple sclerosis/MS drugs in its portfolio are Tecfidera, Vumerity, Avonex, Plegridy, Fampyra and Tysabri. Other approved/marketed products include Fumaderm (severe psoriasis), Spinraza (spinal muscular atrophy (SMA)) and Aduhelm (Alzheimer's disease).
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $172.495B 10.52
GSK (GSK) United Kingdom $71.890B 9.01
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.433B 19.52
Ginkgo Bioworks Holdings (DNA) United States $3.861B 0.00
Myovant Sciences (MYOV) United Kingdom $2.605B 0.00
Arcus Biosciences (RCUS) United States $2.586B 38.82
Biohaven (BHVN) United States $1.141B 0.00
Emergent Biosolutions (EBS) United States $0.599B 4.71
Zymeworks (ZYME) Canada $0.478B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.278B 0.00
Enzo Biochem (ENZ) United States $0.096B 0.00
SQZ Biotechnologies (SQZ) United States $0.046B 0.00
Gelesis Holdings (GLS) United States $0.035B 0.00
Ambrx Biopharma (AMAM) United States $0.019B 0.00